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Abstract
Purpose Investigation of the current practice of diagnostics and treatment in pediatric cancer patients with febrile neutropenia.
Methods On behalf of the German Society for Pediatric Oncology and Hematology and the German Society for Pediatric 
Infectious Diseases, an Internet-based survey was conducted in 2016 concerning the management of febrile neutropenia in 
pediatric oncology centers (POC). This survey accompanied the release of the corresponding German guideline to document 
current practice before its implementation in clinical practice.
Results In total, 51 POCs participated (response rate 73%; 43 from Germany, and 4 each from Austria and Switzerland). 
Identified targets for antimicrobial stewardship concerned blood culture diagnostics, documentation of the time to antibiotics, 
the use of empirical combination therapy, drug monitoring of aminoglycosides, the time to escalation in patients with persist-
ing fever, minimal duration of IV treatment, sequential oral treatment in patients with persisting neutropenia, indication for 
and choice of empirical antifungal treatment, and the local availability of a pediatric infectious diseases consultation service.
Conclusion This survey provides useful information for local antibiotic stewardship teams to improve the current practice 
referring to the corresponding national and international guidelines.
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Introduction
Due to their underlying disease and anticancer treatment, 
pediatric oncology patients are at an increased risk of infec-
tious complications. Fever during neutropenia may be the 
only sign of an infectious episode, but in the majority of 
pediatric cancer patients with fever during neutropenia, the 
focus of the underlying infection remains unclear and cannot 
be documented microbiologically (e.g., bloodstream infec-
tion with a pathogen isolated) or clinically (e.g., pneumonia). 
Because of the risk of a complicated clinical course and the 
spectrum of pathogens causing severe and life-threatening 
bacterial infections in pediatric cancer patients, timely inpa-
tient treatment with broad-spectrum antibiotics is the stand-
ard of care [1, 2].
Despite this consensus, previous surveys performed in 
pediatric cancer centers from different countries revealed 
a high level of heterogeneity in many key topics of clini-
cal management [3–8]. In May 2016, the working group for 
infectious complications in the immunocompromised child 
of the German Society for Pediatric Oncology and Hema-
tology (GPOH) and the German Society for Pediatric Infec-
tious Diseases (DGPI) released consensus recommendations 
[9], concerning the diagnostics and treatment of fever with-
out a focus on neutropenic pediatric cancer patients (FN), 
excluding hematopoietic stem cell transplant recipients and 
children and adolescents with clinical signs of sepsis, sep-
tic shock or infection-related organ failure. The aim of the 
present survey was to explore the institutional standards of 
treatment of FN in pediatric oncology centers (POCs) from 
Germany, Austria, and Switzerland, to compare the cur-
rent clinical practice with the recommendations of the new 
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guideline [9] and to identify targets for improvement from 
the perspective of antimicrobial stewardship.
Methods
Referring to the recent German FN guidelines [9], the 
authors developed an Internet-based anonymized survey 
(Survey Monkey™; San Mateo, USA). The main topics 
and detailed questions were finalized after repeated rounds 
of internal discussion in the GPOH/DGPI working group 
(Supplemental Table 1 contains the questions and the cor-
responding information from the guideline). The survey did 
not include clinical case vignettes [8] and did not collect 
original local standard operation procedure documents [4]. It 
is important to emphasize that (by definition) the FN popu-
lation comprised by the German guideline does not include 
children and adolescents with clinical signs of sepsis, septic 
shock or infection-related organ failure. In total, 70 pediat-
ric oncology centers (POCs) were contacted by e-mail and 
asked for participation. Typically, the head of the department 
or a responsible senior pediatric oncology consultant was 
contacted. One reminder was sent out to hospitals which 
did not reply to the first e-mail. The survey was released 
on March 14, 2016, briefly before publication of the guide-
line [9], and closed on July 27, 2016, i.e., 2 months after 
the publication. The POCs were arbitrarily categorized into 
three different sizes, namely small (≤ 40 newly diagnosed 
patients/year), medium (41–75), and large (> 75) centers. In 
addition, we also analyzed whether the affiliation (university 
hospital vs. academic tertiary care children hospital) affected 
the results.
Standard statistical methods (SPSS Version 24 IBM SPSS 
Statistics) were used to analyze potential correlations of the 
results with the size of the participating POCs. Datasets 
derived from the online protected database were checked 
for duplicates from the same center. Fisher’s test was used 
to examine differences between categorical variables to a 
significance level of 5% (p < 0.05). Since the survey did not 
contain individual patient data, participation was voluntary 
and the participating oncologist consented to the anonymous 
cumulative analysis; an approval by ethics committee was 
not necessary.
Results
Number and characteristics of participating 
institutions and internal guideline
Fifty-one pediatric oncologists from 51 GPOH-affiliated 
POCs participated (response rate 73%; 43 from Germany, 
and 4 each from Austria and Switzerland, respectively); 
however, not all of them answered all questions completely. 
Therefore, we provide the corresponding number of POCs, 
which have answered to a particular question, in parenthesis 
(e.g., 10/51). Sixty-five percent of all 51 POCs were univer-
sity hospitals and 35% were academic tertiary care pediatric 
hospitals. The median number of inpatient pediatric oncol-
ogy beds was 14 (interquartile range; IQR 9–18; min. 4, 
max. 30). In 2015, the median number of newly admitted 
patients (de novo and relapsed malignancies) was 50 (IQR 
33–80; min. 15, max. 170). Ninety percent of the partici-
pating POCs had an internal standard operation procedure 
document detailing the routine management of patients with 
FN. Tables 1, 2, and 3 show the analysis of the correspond-
ing results referring to small, medium, and large centers as 
well as to the affiliation (university vs. academic tertiary care 
children hospital).   
Fever criteria and methods for measuring 
temperature
The survey offered a choice of three different definitions of 
fever, but participants could also enter free-text comments. 
Overall, 78% (40/51) of the POCs use the definition “tem-
perature once > 38.5 °C or > 38 °C with repeated measure-
ment after one hour”; 2% (n = 1) use “once > 39 °C” and 6% 
(n = 3) once > 38 °C. Concerning the method of temperature 
measurement, we asked about the current standards in inpa-
tients (Fig. 1). Remarkably, 41% of the POCs did not have 
a defined standard method for temperature measurement in 
outpatients (data not shown).
Vital signs on admission
Vital signs documented by all centers (n = 51) in a patient 
admitted with FN are temperature (100%), heart rate (100%), 
blood pressure (100%), and actual body weight (98%). With 
lower frequencies, the POCs document respiratory rate in 
55% (28/51), oxygen saturation at room air (pulse oximetry) 
in 75% (38/51), and median arterial pressure in 78% (40/51; 
 RRdiast plus 1/3 of the difference  RRsyst − RRdiast).
Blood cultures
Nearly all POCs (96%; 49/51) sample blood cultures only 
from the central venous access device (if present), whereas 
only two (4%) regularly also collect blood cultures from a 
peripheral vein. Figures 2 and 3 show further details of the 
local standard of blood culture diagnostics.
Only two centers (4%; 10/51) regularly draw blood cul-
tures 24 h after the onset of antibiotic treatment, 20% (10/50) 
of the centers draw cultures once daily in patients with ongo-
ing fever despite antibiotic treatment, and 46% (23/50) of the 
institutions draw repeat blood cultures only in patients with 
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Table 1  Comparison of the statistical significance (Fisher’s exact test) concerning the type of pediatric oncology centers (POCs): university hos-
pital vs. academic tertiary pediatric care facility




pediatric care facility 
(n = 18)
Statistical significance 
(Fisher’s exact test, p 
values)
Standard blood cultures (1)
Which blood culture vials are 
utilized?
a) Only aerobic culture vial 4 2 0.472
b) Aerobic and anaerobic culture vial 28 15
c) Additional mycosis culture vial 0 1
Standard blood cultures (2)
From which access is the blood sam-
ple for the cultures taken from?
a) Only from the Broviac/Port-A-
Cath
31 18 0.534
b) From the Broviac/Port-A-Cath 
and peripheral venous
2 0
c) Only peripheral venous 0 0
Standard blood cultures (3)
Which volume is taken from a child 
with a body weight of 15 kg?
a) 1–3 ml per vial (z.B. Bactec® 
Paeds)
11 8 0.073
b) 3–5 ml per vial 16 8
c) 5–10 ml per vial 6 2
Laboratory tests on admission to the 
hospital—blood count?
a) Yes 33 18 Ø
b) No 0 0
Laboratory tests on admission to the 
hospital—CRP?
a) Yes 33 18 Ø
b) No 0 0
Laboratory tests on admission to the 
hospital—interleukin 8?
a) Yes 0 0 Ø
b) No 33 18
Laboratory tests on admission to the 
hospital—interleukin 6?
a) Yes 2 0 0.534
b) No 31 18
Laboratory tests on admission to the 
hospital—procalcitonin?
a) Yes 5 6 0.164
b) No 28 12
Laboratory tests on admission to the 
hospital—liver function tests?
a) Yes 30 18 0.544
b) No 3 0
Laboratory tests on admission to the 
hospital—creatinine?
a) Yes 32 18 1.000
b) No 1 0
Laboratory tests on admission to the 
hospital—coagulation tests?
a) Yes 13 10 0.378
b) No 20 8
Laboratory tests on admission to the 
hospital—blood gas analysis?
a) Yes 19 11 1.000
b) No 14 7
Is a urine sample analyzed at all 
times?
a) Yes 20 17 0.010
b) No 13 1
“Time to antibiotics (TTA)”
Is the exact period of time between 
the time point of admission to the 
hospital and the first dose of antibi-
otics documented?
a) Yes 15 10 0.551
b) No 18 7
First-line antibiotic treatment 
regime: for a pediatric cancer 
patient with fever in neutropenia 
without a focus we generally use:
a) An empiric monotherapy 17 9 1.000
b) An empiric combination therapy 16 8
Does there exist a fixed rule when 
to add an antimycotic agent for 
patients at high risk for an invasive 
fungal infection with persistent 
fever without a focus?
a) After 72 h 12 8 0.922
b) After 96 h 9 4
c) According to individual decisions 8 4
d) According to own specifications 4 1
Is the antibiotic treatment gener-
ally switched in clinically stable 
patients with persistent fever? If 
the answer is yes, at which time 
point does this switch take place?
a) After 48 h 16 8 1.000
b) After 72 h 10 5
c) According to individual decisions 7 4
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persistent fever prior to the escalation of empiric antibiotic 
treatment (e.g., after 48–96 h).
Further laboratory diagnostics
On admission of a patient with FN, all centers order a 
peripheral blood cell count (including a differential WBC), 
a serum C-reactive protein, creatinine, and transaminases 
(ALT, AST). Additional surrogate parameters indicating 
systemic inflammation and infection such as interleukin 6, 
interleukin 8, and procalcitonin are regularly determined in 
none, 4% (2/51), and 22% (11/51) of all centers. 73% (37/51) 
perform a urine dipstick test with or without a urine culture 
in case of positive findings. This practice was significantly 
seen more often in academic teaching hospitals compared to 
university hospitals [94% (17/18) vs. 61% (20/33); p = 0.01; 
Table 1]. Thirty-one (59%; 31/51) stated to perform a venous 
blood gas analysis on admission; details (e.g., concerning 
the availability of lactate levels) were not asked for.
Availability of PCR based viral diagnostics
Only 2 of 51 POCs (4%) did not have the availability to 
detect viral pathogens in respiratory secretions by (rt)PCR 
methods (Fig. 4). Sixty-seven percent of all POCs are capa-
ble of performing multiplex PCRs to detect a defined panel 
of respiratory viral pathogens. 
Time to antibiotics
The lag time or the interval from the time of admission to 
the time of the first antibiotic administration is documented 
regularly in 50% (25/50) of all POCs, without significant 
difference between small, medium, and large centers [48% 
(10/21) vs. 67% (10/15) vs. 33% (5/15), respectively].
First‑line antibiotic therapy
Half of all centers (52%; 26/50) use antibacterial monother-
apy as first-line treatment of neutropenic pediatric oncology 
patients with fever without a focus, and 48% (24/50) use an 
empirical combination therapy. The proportion of small size 
centers using combination therapy (80%) is larger than the 
corresponding proportion in median (47%) and large centers 
(33%; difference statistically not significant).
The preferred first-line betalactam antibiotic in most 
POCS (61%; 30/49) is piperacillin–tazobactam, followed by 
ceftazidime (24%; 12/49), cefepime and ceftriaxone (4%; 
Table 1  (continued)




pediatric care facility 
(n = 18)
Statistical significance 
(Fisher’s exact test, p 
values)
How long is the minimum dura-
tion of iv antibiotic treatment in 
pediatric cancer patients with FN 
(good clinical condition, sterile 
initial blood cultures and no fever 
or at least 24 h)?
a) < 48 h 2 0 0.271
b) 48 h 10 2
c) 72 h 14 8
d) > 72 h 7 7
Do you usually stop iv antibiotic 
treatment despite the occurrence of 
leukocyte recovery?
a) Yes 21 8 0.366
b) No, recovery of leukocytes 
required
12 9
Do patients receive an oral antibi-
otic continuation treatment whose 
fever has resolved but who are still 
neutropenic?
a) Yes 6 3 0.908
b) No 7 2
c) In particular cases 20 12
Are there regular interdisciplinary 
conferences of pediatric hematolo-
gists/oncologists and microbiolo-
gists held to analyze data on inva-
sive pathogens and their in vitro 
sensitivity profile for a defined 
retrospective period of time (e.g., 
every 6 or 12 months)?
a) Yes 14 8 0.773
b) No 19 9
Does a regular clinical visit with a 
pediatric infectious disease special-
ist (or optionally with a clinical 
microbiologist) take place in your 
pediatric oncology center?
a) Yes 18 5 0.136
b) No 15 12
Bold value indicates significant results (p < 0.05)
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Table 2  Comparison of the statistical significance (Fisher’s exact test) concerning the center size: “small vs. medium large vs. large” pediatric 
oncology centers (POCs)









(Fisher’s exact test, p 
values)
Standard blood cultures (1)
Which blood culture vials are 
utilized?
a) Only aerobic culture vial 2 1 3 0.631
b) Aerobic and anaerobic culture 
vial
18 14 11
c) Additional mycosis culture vial 1 0 0
Standard blood cultures (2)
From which access is the blood 
sample for the cultures taken 
from?
a) Only from the Broviac/Port-A-
Cath
20 14 15 1.000
b) From the Broviac/Port-A-Cath 
and peripheral venous
1 1 0
c) Only peripheral venous 0 0 0
Standard blood cultures (3)
Which volume is taken from a child 
with a body weight of 15 kg?
a) 1–3 ml per vial (z.B. Bactec® 
Paeds)
9 5 5 0.073
b) 3–5 ml per vial 12 7 5
c) 5–10 ml per vial 0 3 5
Laboratory tests on admission to 
the hospital—blood count?
a) Yes 21 15 15 Ø
b) No 0 0 0
Laboratory tests on admission to 
the hospital—CRP?
a) Yes 21 15 15 Ø
b) No 0 0 0
Laboratory tests on admission to 
the hospital—interleukin 8?
a) Yes 0 0 0 Ø
b) No 21 15 15
Laboratory tests on admission to 
the hospital—interleukin 6?
a) Yes 1 0 1 1.000
b) No 20 15 14
Laboratory tests on admission to 
the hospital—procalcitonin?
a) Yes 5 2 4 0.755
b) No 16 13 11
Laboratory tests on admission to 
the hospital—liver function tests?
a) Yes 20 15 13 0.471
b) No 1 0 2
Laboratory tests on admission to 
the hospital—creatinine?
a) Yes 21 15 14 0.588
b) No 0 0 1
Laboratory tests on admission to 
the hospital—coagulation tests?
a) Yes 5 10 8 0.030
b) No 16 5 7
Laboratory tests on admission to 
the hospital—blood gas analysis?
a) Yes 10 9 11 0.376
b) No 11 6 4
Is a urine sample analyzed at all 
times?
a) Yes 17 12 8 0.180
b) No 4 3 7
“Time to antibiotics (TTA)”
Is the exact period of time between 
the time point of admission to 
the hospital and the first dose of 
antibiotics documented?
a) Yes 10 10 5 0.209
b) No 10 5 10
Firs-line antibiotic treatment 
regime: for a pediatric cancer 
patient with fever in neutropenia 
without a focus we generally use:
a) An empiric monotherapy 8 8 10 0.291
b) An empiric combination therapy 12 7 5
Does there exist a fixed rule when 
to add an antimycotic agent 
for patients on high risk for an 
invasive fungal infection with 
persistent fever without a focus?
a) After 72 h 7 7 6 0.687
b) After 96 h 5 3 5
c) According to individual deci-
sions
4 4 4
d) According to own specifications 4 1 0
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Table 2  (continued)









(Fisher’s exact test, p 
values)
Is the antibiotic treatment gener-
ally switched in clinically stable 
patients with persistent fever? If 
the answer is yes, at which time 
point does this switch take place?
a) After 48 h 9 8 7 0.927
b) After 72 h 6 5 4
c) According to individual deci-
sions
5 2 4
How long is the minimum dura-
tion of iv antibiotic treatment in 
pediatric cancer patients with FN 
(good clinical condition, sterile 
initial blood cultures and no fever 
or at least 24 h)?
a) < 48 h 1 0 1 0.765
b) 48 h 5 3 4
c) 72 h 8 6 8
d) > 72 h 6 6 2
Do you usually stop iv antibiotic 
treatment despite the occurrence 
of leukocyte recovery?
a) Yes 10 10 9 0.673
b) No, recovery of leukocytes 
required
10 5 6
Do patients receive an oral antibi-
otic continuation treatment whose 
fever has resolved but who are 
still neutropenic?
a) Yes 4 4 1 0.705
b) No 4 2 3
c) In particular cases 12 9 11
Are there regular interdiscipli-
nary conferences of pediatric 
hematologists/oncologists and 
microbiologists held to analyze 
data on invasive pathogens and 
their in vitro sensitivity profile for 
a defined retrospective period of 
time (e.g., every 6 or 12 months)?
a) Yes 5 6 11 0.020
b) No 15 9 4
Does a regular clinical visit with 
a pediatric infectious diseases 
specialist (or optionally with a 
clinical microbiologist) take place 
in your pediatric oncology center?
a) Yes 8 5 10 0.152
b) No 12 10 5
Bold values indicate significant results (p < 0.05)
Table 3  Interdisciplinary conferences concerning antibiograms of invasive pathogens and infectious disease consultations
Bold value indicates significant results (p < 0.05)
Question 1 Answer options Question 2 Answer options Correlation 
(Fisher’s exact test, 
p-value)
Are there regular interdiscipli-
nary conferences of pediatric 
hematologists/oncologists and 
microbiologists held to analyze 
data on invasive pathogens and 
their in vitro sensitivity profile 
for a defined retrospective 
period of time (e.g., every 6 or 
12 months)?
Yes (n = 22) First-line antibiotic treatment 
regime: for a pediatric cancer 
patient with fever in neutrope-
nia without a focus we gener-
ally use:
An empiric monotherapy (n = 13) 0.407
An empiric combination therapy 
(n = 9)
No (n = 28) An empiric monotherapy (n = 13)
An empiric combination therapy 
(n = 15)
Does a regular clinical visit with 
a pediatric infectious diseases 
specialist (or optionally with 
a clinical microbiologist) take 
place in your pediatric oncology 
center?
Yes (n = 23) An empiric monotherapy (n = 16) 0.027
An empiric combination therapy 
(n = 7)
No (n = 27) An empiric monotherapy (n = 10)
An empiric combination therapy 
(n = 17)
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2/49) each, the latter in combination with amikacin). Only 
three POCs (6%) use imipenem/cilastatin or meropenem as 
first-line treatment. Forty-four of 49 POCs (86%) provided 
specific information regarding the use of aminoglycosides 
(AGL) combination treatment; of those, 55% (24/49) prefer 
tobramycin, 34% (15/49) gentamicin, and 11% (5/49) ami-
kacin. Nearly all POCs (94%; 45/48) administer AGLs once 
daily. Of 48 POCs responding to this question, 71% (N = 34) 
assess AGL trough levels even in patients with normal serum 
creatinine, whereas 21% (10/48) do not measure AGL trough 
levels regularly. In contrast, AGL peak levels (Cmax) are 
determined in only 8% (4/48). The exact time point of trough 
level sampling differed substantially between the POCs (data 
not shown).
Time to escalation in patients with persisting fever
In patients with persisting FN, who are in stable clinical 
condition without microbiologically or clinically defined 
infection, 48% of POCs (24/50) change (escalate) the ini-
tial empirical antibacterial regimen after 48 h, 30% (15/50) 
after 72 h, and 22% (11/50) after clinical reassessment on 
an individual case to case basis.
Minimum duration of IV antibiotic treatment
In patients, who are in a good clinical condition with nega-
tive initial blood cultures and no fever in the last 24 h, two 
POCs (4%; 2/50) state to execute a minimal IV treatment 
duration below 48 h. The minimum duration of IV treatment 
is 48 h in 24% (12/50), and 72 h in 44% (22/50). Twenty-
eight percent (14/50) of all POCs treat these patients for 
more than 72 h. University hospitals have a shorter mini-
mal treatment duration than academic teaching hospitals 
[> 72 h in 21% (7/33) vs. 42% (7/18 = 42%); difference not 
significant].
Concerning the recovery of leukocyte counts, more than 
half of the POCs (58%; 29/50) do not require the recovery 
of the leukocytes (e.g., neutrophils > 0.5 × 10/9/L) for the 
decision to stop the IV ABT, whereas 42% (21/50) of all 
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Fig. 4  Availability of (rt)PCR-based methods to detect viral patho-
gens in respiratory secretions
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Eighty-six percent of all POCs discharge the patient on the 
same day on which antibacterial treatment is discontinued.
In patients, in whom the IV ABT is stopped despite persis-
tent neutropenia, 18% (9/50) never continue with oral antibiot-
ics, 64% (32/50) of all POCs continue treatment with an oral 
antibiotic in selected cases, and 18% (9/50) regularly continue 
with sequential oral therapy. In the nine centers, which stated 
to use sequential oral therapy in patients with persisting neu-
tropenia, eight different antibiotics (antibiotic combinations) 
are utilized including ciprofloxacin in four centers.
Empirical antifungal treatment
Twenty of 50 POCs (40%) start empirical antifungal treat-
ment (AFT) in patients at high risk of invasive fungal infec-
tion (IFI) after 72 h of fever unresponsive to broad-spectrum 
antibiotics, whereas 26% (13/50) start AFT after 96 h; 24% 
(12/50) decide on the indication on an individual case-to-
case basis. The preferred first-line antifungals for empirical 
AFT in FN patients are (multiple answers allowed): lipo-
somal amphotericin B (AmBisome™) 84% (43/51), caspo-
fungin 16% (8/51), and voriconazole 14% (7/51). In one 
POC each, the attending physicians recommend micafungin 
or conventional amphotericin B.
Interdisciplinary conferences and infectious disease 
consultation
Regular interdisciplinary conferences of pediatric hema-
tologists/oncologists and microbiologists to analyze data 
on invasive pathogens and their in vitro sensitivity profile 
take place in 46% (23/50) of all POCs. Regarding center 
size, large centers perform these meetings in 73% (11/15), 
small centers in 25% (5/21) and median-sized centers in 40% 
(6/15; p = 0.20; Table 2). The proportion of POCs using first-
line monotherapy is lower in centers, which regularly organ-
ize such an interdisciplinary conference [41% (13/28) vs. 
54% (13/21); p = 0.41]. Of all POCs (n = 50), 54% (n = 27) 
do not have the opportunity to consult a pediatric infectious 
disease specialist at their institution. The availability of a 
pediatric infectious disease consultation service is greater 
in large centers [67% (10/15) vs. 40% (8/20) in small POCs; 
p = 0.152) and in university hospitals relative to academic 
teaching hospitals [55%; (18/33) vs. 29% (5/17); p = 0.136]. 
POCs in which a pediatric infective disease consultation 
is performed regularly, less often use empiric first-line 
combination therapy is used [30% (7/23) vs. 63% (17/27); 
p = 0.027; Table 3).
Discussion
This multicenter survey describes the current clinical prac-
tice of the management of FN without a clinically or micro-
biologically defined focus on POCs in Germany, Austria, 
and Switzerland. The response rate (73%) is in the upper 
range of comparable surveys from other countries [4, 8, 10].
Most POCs in Germany, Austria, and Switzerland are 
affiliated at University hospitals or academic tertiary care 
pediatric facilities, which reflects the current situation 
in these countries with few small- and large-, but many 
medium-size POCs. Since our survey was performed in par-
allel to the release of the 2016 German AWMF guideline 
[9], the results depict the situation before the main com-
ponents and recommendations of this guideline could be 
implemented. However, it is important to note that the inter-
national guidelines on FN in the pediatric setting have been 
available starting in 2012 (updated in 2017 [11]. The Ger-
man guideline differs only in a few issues from these interna-
tional guidelines [12], including that the German guideline 
is not applicable to patients, who need intensive care due to 
severe sepsis, it does not recommend a priori risk stratifica-
tion in high- and low-risk groups, and it argues against the 
use of meropenem (a carbapenem) as first-line treatment in 
stable patients. One important purpose of this survey was to 
identify potential targets for antibiotic stewardship (ABS).
More than 90% of all participating POCs have a defined 
internal standard operation procedure concerning the man-
agement of FN. Most POCs used the same definition for 
fever and neutropenia [13, 14]. Remarkably, 41% of the par-
ticipating POCs do not recommend one defined standard 
method for temperature measurement in outpatients. The 
definition of fever and the method of temperature measure-
ment should be harmonized, also to enable comparison of 
results between POCs [15]. Otherwise, a specific patient 
may or may not be hospitalized and treated with IV anti-
biotics only depending on the POC he attends to [3]. In 
pediatric oncology patients with FN, the timely detection of 
those patients with severe sepsis is of utmost importance, 
since clinical management in case of severe sepsis clearly 
differs from patients who only have FN [16]. Most POCS 
follow the German guidelines [9] and draw at least one blood 
culture set from the central venous access device (CVAD) 
before they start empiric antibiotic treatment (eABT). In our 
survey, only half of all POCs (47%) recognize that there 
is a minimal blood culture volume required for in a child 
with a bodyweight of 15 kg (at least 5 ml per bottle) [17, 
18], whereas some use bottles provided for culturing 1–3 ml 
of blood from neonates and infants < 10 kg in all patients. 
This practice may significantly reduce blood culture sensi-
tivity. The question, whether more than at least one blood 
culture set drawn on day 1 and on day 2 of treatment is of 
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any benefit for the clinical management, remains a matter of 
debate [19, 20]. Rosenblum et al. analyzed 220 FN episodes 
in 105 patients and identified a pathogen in 11% of repeated 
cultures drawn in those patients with persistent fever [21]. 
If the initial blood culture has yielded a pathogen, control 
cultures are mandatory to guide further therapy and to con-
firm that a single positive culture yielding, e.g., coagulase-
negative staphylococci is not a contamination.
The heterogeneous utilization of different biomarkers in 
our survey reflects that in febrile neutropenic patients with-
out a focus, no biomarker is capable to definitely confirm 
or exclude a bacterial infection and to predict the clinical 
course [22]. Relying on experience (not on study results), 
most POCs use the C-reactive protein to confirm the 
response to antibiotic treatment. In some patients, leuko-
cyte recovery is accompanied by a second increase in CRP 
values.
Minimizing the time to antibiotics (TTA) has been 
defined as an important goal of treatment; there seems to be 
an association between longer TTA and impaired safety [23]. 
Half of all POCs regularly document the TTA. In general, 
the GPOH guideline [9] recommends a first-line monother-
apy with piperacillin–tazobactam, ceftazidime or cefepime 
(the latter two agents not in patients with severe mucosi-
tis). In contrast to the international guidelines [11, 24], the 
German guideline strictly argues against the empirical use 
of carbapenems in the first-line treatment of pediatric FN 
to avoid the selection of carbapenem-resistant pathogens. 
Empirical use of meropenem is recommended in case of 
clinical signs of a severe infection or sepsis, and may be con-
sidered in patients colonized (or previously infected) with 
ESBL-producing bacteria [25–27].
Keeping in mind the very low incidence of bloodstream 
infections due to ESBL-producing Gram-negative Entero-
bacteriacerales in recent studies from Germany, Switzer-
land, and the Netherlands [28, 29], the reason for the high 
percentage of POCs using initial combination therapy (48%) 
remains unclear. In this respect, national [9] and interna-
tional guidelines [11] may help to promote substantial 
changes in clinical management concerning initial mono-
therapy [30]. Other surveys and multicenter evaluations 
addressed this issue too [3, 31]. In Switzerland, the use of 
ceftriaxone plus amikacin adds antipseudomonal activity to 
ceftriaxone [32].
In cases with AGL combination treatment, most POCs 
use tobramycin or gentamicin as short time infusion once 
daily. Nowadays, this mode of administration represents the 
state of the art [33, 34]. Interestingly, only 8% of all POCs 
determine the Cmax (target: 8–10 × MIC; e.g., 10–20 mg/L, 
referring to an MIC of 2 µg/ml) to evaluate the appropri-
ateness of individual AGL dosing. In addition, out of all 
POCs, 20% do not regularly determine AGL trough levels 
in patients with normal serum creatinine, although many of 
these patients may have received other potentially nephro-
toxic or ototoxic treatments (e.g., platinum derivatives, 
furosemide, irradiation, etc.). This topic of supportive care 
would probably benefit from a less heterogeneous approach.
The GPOH guideline recommends escalating the empiric 
ABT in stable patients with persistent fever after 72 h if 
the patient shows neutropenia without signs of recovery 
[9]. This cutoff (72 h) has been established in many stud-
ies investigating the use of different empirical antibiotics 
[30]. There is no data confirming the benefit of changing 
the eABT earlier in a stable patient (e.g., after 48 h, as done 
by 48% of the POCs). Some POCs (22%) decide about this 
question on an individual basis. This may include the deci-
sion not to change the initial eABT in a stable patient whose 
neutrophils are expected to recover in the next few days [11]. 
Watchful waiting at least 72 h or even longer in this situa-
tion may reduce the cumulative consumption of second- and 
third-line ABT.
Irrespective of hematological recovery, nearly two-thirds 
of all POCs (58%) stop antibiotics in a stable patient with 
negative cultures, who is afebrile for 24 h, and has no severe 
mucositis or clinical signs of a focal infection. The GPOH 
guideline [9] clearly supports this approach, but argues 
against the oral continuation of eABT in most cases.
In neutropenic patients, many POCs (68%) discharge the 
patient but continue treatment with oral antibiotics. Remark-
ably, those centers mentioned eight different oral antibiotics/
antibiotic combinations, including fluoroquinolones. This 
heterogeneity clearly reflects a lack of evidence, since the 
risk of secondary infection, in particular with P. aeruginosa 
(fluoroquinolones) [35] in patients eligible for oral sequence 
treatment is very low [36, 37].
About one-third of all POCs continue IV treatment for 
more than 72 h. This may negatively affect the quality of life 
of the patients and their families and increases the risk of 
nosocomial infections [38]. Concerning empirical antifungal 
treatment (eAFT), the guideline defines certain groups with 
high risk of invasive fungal infection (IFI) [39]. The guide-
line suggests using liposomal amphotericin B or caspofungin 
after 96 h of fever despite eABT [9], and provides details 
on diagnostic tools to confirm or exclude an IFI, as much 
as possible. Notably, 14% of all POCs use voriconazole for 
eAFT, although this drug is not licensed for eAFT and needs 
therapeutic drug monitoring [40].
The final questions of the survey tried to elucidate the 
access to some core elements of Antibiotic Stewardship 
(ABS) programs in this particular setting, more precisely.
– Interdisciplinary conferences to discuss the POC’s cumu-
lative antibiogram (e.g., pathogens detected in blood 
cultures and their in vitro sensitivity) with clinicians, 
microbiologists, infectious disease specialists, and IPC 
personnel.
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– A prospective audit and feedback service provided by 
pediatric infectious disease (PID) specialists from an 
ABS team [41].
Such interdisciplinary conferences take place in only 46% 
of all POCs. In addition, only 46% of all POCs have access 
to PID consultations, which reflects the profound shortage 
of PID specialists in pediatric health-care facilities in Ger-
many. Interestingly, university centers more often have PID 
services, and POCs with PID support less often use first-line 
combination therapy in pediatric patients with FN. Hope-
fully, the emerging threat of infections due to multidrug-
resistant pathogens and adverse short- and long-term effects 
of inadequate ABT will lead to the implementation of ABS 
programs in all POCs in the near future.
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